# Cambrex advances $120M API plant expansion in Iowa and R&D buildout in Italy

Cambrex completed initial engineering studies for a new large-scale API manufacturing plant in Charles City, Iowa, as part of a $120 million U.S. expansion, with groundbreaking scheduled for late 2026. In Milan, Italy, a $30 million expansion adding analytical development and process R&D capabilities is underway, expected to complete in H2 2027.

- Type: Expansion
- Announced: 2026-04-01
- Where: Charles City, Iowa, United States
- Value: $120.0M
- Status: announced
- Capacity: 140,000 liters
- Products: active pharmaceutical ingredients (APIs)
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Cambrex](https://endata.com/companies/27131.md)

## Sources

- [megaproject.com](https://www.megaproject.com/news/factory/cambrex-advances-120m-api-plant-expansion-in-iowa-r-d-buildout-in-italy), 2026-04-01: "Cambrex, a contract development and manufacturing organization (CDMO) headquartered in East Rutherford, New Jersey, has completed initial engineering studies for a new large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.